NiKang Therapeutics
Daniel Ryan has worked in a variety of roles since 2003. Daniel began their career as an Intern at Ryan & Coscia in 2006, followed by a role as Res. Life at Merrimack College in 2003. In 2007, they joined Deloitte as an Audit Services and Audit In-Charge. In 2013, they moved to Ziopharm Oncology as an Assistant Controller and Accounting Manager. In 2019, they became Director/Controller at Oncorus, Inc. and, in 2021, they joined NiKang Therapeutics Inc. and Ziopharm Oncology as Executive Director, Controller.
Daniel Ryan attended Bentley University from 2007 to 2009, where they obtained a Post Grad degree in Accountancy. Before that, they attended Merrimack College from 2003 to 2007, where they obtained a Bachelor of Science in Business - Accounting.
This person is not in any offices
NiKang Therapeutics
NiKang Therapeutics, Inc. is a privately-held biotech company focused on developing novel small molecule oncology drug discovery. Their mission is to discover and develop first-in-class, and/or best-in-class small molecule targeted therapies and immuno-oncology (I-O) drugs to help cure cancers.